Facilitating Innovative Nuclear Diagnostics Act of 2023

Bill 118 hr 1199, also known as the Facilitating Innovative Nuclear Diagnostics Act of 2023, aims to promote the development and use of innovative nuclear diagnostic technologies in the United States. The bill recognizes the importance of nuclear diagnostics in advancing medical research and improving patient care.

The key provisions of the bill include establishing a grant program to support research and development of new nuclear diagnostic technologies, as well as providing funding for training programs to educate healthcare professionals on the use of these technologies. The bill also calls for the establishment of a national registry to track the use and outcomes of nuclear diagnostic procedures.

Additionally, the bill seeks to streamline the regulatory approval process for new nuclear diagnostic technologies, in order to expedite their availability to patients. This includes provisions for the FDA to collaborate with industry stakeholders to develop guidelines for the approval of these technologies. Overall, the Facilitating Innovative Nuclear Diagnostics Act of 2023 aims to foster innovation in the field of nuclear diagnostics, improve patient outcomes, and advance medical research in the United States.